JP4943504B2 - 循環腫瘍細胞アッセイ - Google Patents

循環腫瘍細胞アッセイ Download PDF

Info

Publication number
JP4943504B2
JP4943504B2 JP2009512704A JP2009512704A JP4943504B2 JP 4943504 B2 JP4943504 B2 JP 4943504B2 JP 2009512704 A JP2009512704 A JP 2009512704A JP 2009512704 A JP2009512704 A JP 2009512704A JP 4943504 B2 JP4943504 B2 JP 4943504B2
Authority
JP
Japan
Prior art keywords
igf
sample
patient
cells
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009512704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009539097A5 (cg-RX-API-DMAC7.html
JP2009539097A (ja
Inventor
グアルベルト アントニオ
マリア ロバーツ ルイーザ
リン メルヴィン キャリー
アイ. レポレット マデリン
アレン チアニーズ デイヴィッド
カール コネリー マーク
ウェンデリナス マチアス マリエ タースタッペン レオナルダス
Original Assignee
ファイザー・プロダクツ・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・プロダクツ・インク filed Critical ファイザー・プロダクツ・インク
Publication of JP2009539097A publication Critical patent/JP2009539097A/ja
Publication of JP2009539097A5 publication Critical patent/JP2009539097A5/ja
Application granted granted Critical
Publication of JP4943504B2 publication Critical patent/JP4943504B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Sampling And Sample Adjustment (AREA)
JP2009512704A 2006-06-02 2007-05-29 循環腫瘍細胞アッセイ Expired - Fee Related JP4943504B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81081106P 2006-06-02 2006-06-02
US60/810,811 2006-06-02
PCT/IB2007/001483 WO2007141626A1 (en) 2006-06-02 2007-05-29 Circulating tumor cell assay

Publications (3)

Publication Number Publication Date
JP2009539097A JP2009539097A (ja) 2009-11-12
JP2009539097A5 JP2009539097A5 (cg-RX-API-DMAC7.html) 2010-07-15
JP4943504B2 true JP4943504B2 (ja) 2012-05-30

Family

ID=38476880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009512704A Expired - Fee Related JP4943504B2 (ja) 2006-06-02 2007-05-29 循環腫瘍細胞アッセイ

Country Status (19)

Country Link
US (4) US8940493B2 (cg-RX-API-DMAC7.html)
EP (1) EP2027470B1 (cg-RX-API-DMAC7.html)
JP (1) JP4943504B2 (cg-RX-API-DMAC7.html)
KR (3) KR20090023423A (cg-RX-API-DMAC7.html)
CN (1) CN101600966B (cg-RX-API-DMAC7.html)
AU (1) AU2007255110B8 (cg-RX-API-DMAC7.html)
BR (1) BRPI0712225A8 (cg-RX-API-DMAC7.html)
CA (1) CA2653745C (cg-RX-API-DMAC7.html)
DK (1) DK2027470T3 (cg-RX-API-DMAC7.html)
ES (1) ES2397971T3 (cg-RX-API-DMAC7.html)
IL (1) IL195577A (cg-RX-API-DMAC7.html)
MX (1) MX2008015425A (cg-RX-API-DMAC7.html)
NZ (1) NZ573187A (cg-RX-API-DMAC7.html)
PL (1) PL2027470T3 (cg-RX-API-DMAC7.html)
PT (1) PT2027470E (cg-RX-API-DMAC7.html)
RU (1) RU2429486C2 (cg-RX-API-DMAC7.html)
SI (1) SI2027470T1 (cg-RX-API-DMAC7.html)
WO (1) WO2007141626A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200810203B (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006292278B2 (en) 2005-09-20 2012-03-08 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2007255110B8 (en) 2006-06-02 2014-04-10 Pfizer Products Inc. Circulating tumor cell assay
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
US8048621B2 (en) 2007-10-03 2011-11-01 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2008307634A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20090258365A1 (en) * 2008-03-25 2009-10-15 Terstappen Leon W M M METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH
UY32317A (es) 2008-12-12 2010-07-30 Boehringer Ingelheim Int Anticuerpos anti-igf
JP6352588B2 (ja) 2009-10-21 2018-07-04 ザ スクリプス リサーチ インスティテュート 希少ではない細胞を用いて希少細胞を検出する方法
WO2011083391A2 (en) * 2010-01-05 2011-07-14 Pfizer Inc. Biomarkers for anti-igf-ir cancer therapy
WO2012051390A1 (en) * 2010-10-14 2012-04-19 Veridex, Llc Methods and kits for the detection of circulating tumor cells in pancreatic patients using polyspecific capture and cocktail detection reagents
EP2668505A4 (en) * 2011-01-24 2014-05-21 Epic Sciences Inc METHOD FOR OBTAINING INDIVIDUAL CELLS AND APPLICATIONS FROM INDIVIDUAL YTOMICS
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ,エルエルシー 癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用
US9618515B2 (en) * 2011-07-21 2017-04-11 Janssen Diagnostics, Llc Assay to capture and detect circulating multiple myeloma cells from blood
WO2013036620A1 (en) * 2011-09-06 2013-03-14 Becton, Dickinson And Company Methods and compositions for cytometric detection of rare target cells in a sample
WO2014028378A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Methods and systems for detecting biological components
KR101850591B1 (ko) 2012-10-05 2018-04-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
EP3572788B1 (en) * 2012-10-26 2022-03-16 Fluidigm Canada Inc. Method for interrogating a biological sample
US9396532B2 (en) * 2012-11-15 2016-07-19 Siemens Healthcare Diagnostics, Inc. Cell feature-based automatic circulating tumor cell detection
CA3106271A1 (en) 2013-01-25 2014-07-31 Xcell Biosciences, Inc. Methods, compositions, kits, and systems for selective enrichment of target cells
US20150233932A1 (en) * 2013-02-19 2015-08-20 Ching-Ping Tseng Methods, Systems, and Compositions for Enrichment of Rare Cells
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
EP3502270B1 (en) 2013-10-21 2020-03-18 The General Hospital Corporation Methods relating to circulating tumor cell clusters and the treatment of cancer
CN103630440A (zh) * 2013-11-28 2014-03-12 武汉大学 一种循环肿瘤细胞的富集方法
WO2015112955A1 (en) 2014-01-27 2015-07-30 Epic Sciences, Inc. Circulating tumor cell diagnostics for prostate cancer biomarkers
CN106061998B (zh) * 2014-02-05 2020-12-11 弗吉瑞必欧诊断股份公司 用于检测恶性赘生性疾病的组合物和方法
US10545151B2 (en) 2014-02-21 2020-01-28 Epic Sciences, Inc. Methods for analyzing rare circulating cells
CN103940997B (zh) * 2014-03-21 2017-01-04 上海柏慧康生物科技有限公司 一种乳腺癌循环肿瘤细胞检测系统及试剂盒
KR101656037B1 (ko) * 2014-04-30 2016-09-08 울산과학기술원 희소 세포 분리장치, 희소 세포 분리 방법 및 이를 이용한 희소 세포 검출 방법
EP3160654A4 (en) 2014-06-27 2017-11-15 The Regents of The University of California Pcr-activated sorting (pas)
WO2016033103A1 (en) * 2014-08-25 2016-03-03 Creatv Microtech, Inc. Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them
CN104345052B (zh) * 2014-09-29 2017-10-20 南通市肿瘤医院 一种荧光负染法检测活细胞的方法
US10434507B2 (en) 2014-10-22 2019-10-08 The Regents Of The University Of California High definition microdroplet printer
CN107530654A (zh) 2015-02-04 2018-01-02 加利福尼亚大学董事会 通过在离散实体中条形码化对核酸进行测序
US20180066223A1 (en) 2015-04-17 2018-03-08 Xcell Biosciences, Inc. Cancer cell enrichment system
EP3286224A4 (en) * 2015-04-22 2018-11-14 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
KR101701618B1 (ko) 2015-06-23 2017-02-13 국립암센터 전도성 고분자를 이용한 세포 유리 dna 검출용 구조체 및 이의 용도
RU2616532C1 (ru) * 2015-12-28 2017-04-17 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ оценки чувствительности опухоли к проводимой химиотерапии больных местно-распространенным раком молочной железы
KR102130872B1 (ko) 2016-04-27 2020-07-06 주식회사 엘지화학 고체 시료의 수분 측정 장치, 고체 시료 수분 함량 측정 방법 및 이미드화율 분석 방법
US11142791B2 (en) 2016-08-10 2021-10-12 The Regents Of The University Of California Combined multiple-displacement amplification and PCR in an emulsion microdroplet
AU2017382905A1 (en) 2016-12-21 2019-07-04 The Regents Of The University Of California Single cell genomic sequencing using hydrogel based droplets
KR102888595B1 (ko) 2017-04-05 2025-11-20 필립모리스 프로덕츠 에스.에이. 유도 가열식 에어로졸 발생 장치 또는 시스템과 함께 사용하기 위한 서셉터
US10501739B2 (en) 2017-10-18 2019-12-10 Mission Bio, Inc. Method, systems and apparatus for single cell analysis
EP3540631A1 (de) 2018-03-15 2019-09-18 Siemens Healthcare GmbH In-vitro-verfahren zum markierungsfreien bestimmen eines zelltyps einer weissen blutzelle
CN109406245A (zh) * 2018-09-12 2019-03-01 中国辐射防护研究院 一种电子线照射对小鼠igf相关蛋白表达影响的检测方法
AU2020280104A1 (en) 2019-05-22 2022-01-20 Mission Bio, Inc. Method and apparatus for simultaneous targeted sequencing of DNA, RNA and protein
WO2021003255A1 (en) 2019-07-01 2021-01-07 Mission Bio Method and apparatus to normalize quantitative readouts in single-cell experiments
KR20240157060A (ko) 2022-03-30 2024-10-31 니뽄 다바코 산교 가부시키가이샤 비연소 가열형 향미 흡인 물품에 이용하는 향미 시트
EP4646208A1 (en) 2023-01-06 2025-11-12 Ideaya Biosciences, Inc. Treatment of er+ breast cancer comprising homologous recombination deficiency using parg inhibitor

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001041959A (ja) * 1999-05-24 2001-02-16 Toray Ind Inc 癌細胞検出システムおよび癌細胞検出キット
JP2002503814A (ja) * 1998-02-12 2002-02-05 イムニベスト・コーポレイション 循環ガン細胞の迅速かつ効率的な単離のための方法および試薬
JP2002529704A (ja) * 1998-10-29 2002-09-10 セル ワークス インコーポレイテッド 単一細胞の複数マーカー特徴付け
JP2004523232A (ja) * 2001-01-23 2004-08-05 プリマゲン ホールディング ベー.フェー. 治療評価の手段と方法
JP2004534210A (ja) * 2001-03-07 2004-11-11 イムニベスト・コーポレイション 希少細胞検出アッセイにおける内部機能対照として用いる標識細胞
JP2005516217A (ja) * 2001-02-16 2005-06-02 イムニベスト・コーポレイション 循環している癌細胞の急速かつ効果的な単離のための方法および試薬
JP2005536181A (ja) * 2002-01-18 2005-12-02 ピエール、ファーブル、メディカマン 新規抗igf−ir抗体およびその使用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551435A (en) * 1983-08-24 1985-11-05 Immunicon, Inc. Selective removal of immunospecifically recognizable substances from solution
US4795698A (en) * 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4925788A (en) * 1986-10-24 1990-05-15 Immunicon Corporation Immunoassay system and procedure based on precipitin-like interaction between immune complex and Clq or other non-immunospecific factor
US5108933A (en) * 1988-09-16 1992-04-28 Immunicon Corporation Manipulation of colloids for facilitating magnetic separations
US5200084A (en) * 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
JP2000508171A (ja) * 1996-04-05 2000-07-04 ザ・ジョンズ・ホプキンス・ユニバーシティ・スクール・オブ・メディシン 希少細胞の富化方法
US20020172987A1 (en) * 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
US6960449B2 (en) * 1999-02-10 2005-11-01 Cell Works Diagnostics, Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use
CA2380953A1 (en) 1999-08-18 2001-02-22 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
WO2003019141A2 (en) * 2001-08-23 2003-03-06 Immunivest Corporation Analysis of circulating tumor cells, fragments, and debris
US7863012B2 (en) * 2004-02-17 2011-01-04 Veridex, Llc Analysis of circulating tumor cells, fragments, and debris
US6670142B2 (en) * 2001-10-26 2003-12-30 The Regents Of The University Of California Method for screening combinatorial bead library, capturing cells from body fluids, and ligands for cancer cells
US20040229294A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
CN1835975B (zh) 2003-08-13 2012-11-21 辉瑞产品公司 经修饰的人类igf-1r抗体
CN101014365B (zh) * 2004-07-16 2011-04-13 辉瑞产品公司 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
US20060045881A1 (en) * 2004-08-26 2006-03-02 Board Of Regents, The University Of Texas System Anti-cancer vaccines
WO2006041453A1 (en) 2004-09-30 2006-04-20 Immunivest Corporation Circulating tumor cells (ctc’s): apoptotic assessment in prostate cancer patients
DK1861509T3 (da) 2005-03-14 2015-12-07 Janssen Diagnostics Llc Fremgangsmåde til forudsigelse af progressionsfri og overordnet overlevelse for hvert opfølgningstidspunkt under behandling af patienter med metastatisk brystkræft under anvendelse af cirkulerende tumorceller
US20070037173A1 (en) * 2005-08-12 2007-02-15 Allard Jeffrey W Circulating tumor cells (CTC's): early assessment of time to progression, survival and response to therapy in metastatic cancer patients
AU2007255110B8 (en) 2006-06-02 2014-04-10 Pfizer Products Inc. Circulating tumor cell assay
US9121801B2 (en) * 2007-10-24 2015-09-01 Biomarker Strategies, Llc Methods and devices for cellular analysis

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002503814A (ja) * 1998-02-12 2002-02-05 イムニベスト・コーポレイション 循環ガン細胞の迅速かつ効率的な単離のための方法および試薬
JP2005010177A (ja) * 1998-02-12 2005-01-13 Immunivest Corp 循環ガン細胞の迅速かつ効率的な単離のための方法および試薬
JP2002529704A (ja) * 1998-10-29 2002-09-10 セル ワークス インコーポレイテッド 単一細胞の複数マーカー特徴付け
JP2001041959A (ja) * 1999-05-24 2001-02-16 Toray Ind Inc 癌細胞検出システムおよび癌細胞検出キット
JP2004523232A (ja) * 2001-01-23 2004-08-05 プリマゲン ホールディング ベー.フェー. 治療評価の手段と方法
JP2005516217A (ja) * 2001-02-16 2005-06-02 イムニベスト・コーポレイション 循環している癌細胞の急速かつ効果的な単離のための方法および試薬
JP2004534210A (ja) * 2001-03-07 2004-11-11 イムニベスト・コーポレイション 希少細胞検出アッセイにおける内部機能対照として用いる標識細胞
JP2005536181A (ja) * 2002-01-18 2005-12-02 ピエール、ファーブル、メディカマン 新規抗igf−ir抗体およびその使用

Also Published As

Publication number Publication date
CN101600966A (zh) 2009-12-09
US20200191793A1 (en) 2020-06-18
KR101467136B1 (ko) 2014-12-01
EP2027470B1 (en) 2012-11-21
IL195577A (en) 2012-12-31
RU2008147415A (ru) 2010-06-10
CN101600966B (zh) 2014-07-02
WO2007141626A8 (en) 2009-01-08
AU2007255110A1 (en) 2007-12-13
KR20140052081A (ko) 2014-05-02
US20100028915A1 (en) 2010-02-04
US8940493B2 (en) 2015-01-27
AU2007255110B8 (en) 2014-04-10
ES2397971T3 (es) 2013-03-12
SI2027470T1 (sl) 2013-01-31
MX2008015425A (es) 2008-12-12
US20180011103A1 (en) 2018-01-11
JP2009539097A (ja) 2009-11-12
IL195577A0 (en) 2009-09-01
AU2007255110B2 (en) 2014-03-20
PL2027470T3 (pl) 2013-03-29
CA2653745C (en) 2013-11-19
RU2429486C2 (ru) 2011-09-20
DK2027470T3 (da) 2013-02-04
BRPI0712225A2 (pt) 2012-07-24
WO2007141626A1 (en) 2007-12-13
CA2653745A1 (en) 2007-12-13
PT2027470E (pt) 2013-01-28
BRPI0712225A8 (pt) 2019-01-22
US20150177252A1 (en) 2015-06-25
ZA200810203B (en) 2020-05-27
NZ573187A (en) 2011-11-25
KR20090023423A (ko) 2009-03-04
EP2027470A1 (en) 2009-02-25
AU2007255110A8 (en) 2014-04-10
KR20130091788A (ko) 2013-08-19
HK1137509A1 (en) 2010-07-30

Similar Documents

Publication Publication Date Title
CA2653745C (en) Circulating tumor cell assay
JP5889883B2 (ja) 血液中の循環黒色腫細胞を使用して黒色腫患者の臨床成果を予測する方法。
KR20100101109A (ko) 혈액 내 순환 흑색종 세포의 자동화된 계산 및 특징화
KR20170094523A (ko) 생물학적 샘플에서 희귀 사건 분석을 위한 고감도 다중매개변수 방법
CA2623445A1 (en) Comprehensive diagnostic testing procedures for personalized anticancer chemotherapy (pac)
WO2016033103A1 (en) Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them
Ryu et al. Impact of serum HER2 levels on survival and its correlation with clinicopathological parameters in women with breast cancer
EP4374168A1 (en) Methods for predicting and/or monitoring cancer treatment response using changes in circulating cancer associated macrophage-like cells (camls)
HK1137509B (en) Circulating tumor cell assay
US20200355699A1 (en) Biomarkers, test method, and test kit for predicting therapeutic effect of anti-vegfr-2 antibody drug
JP7042753B2 (ja) 免疫チェックポイント阻害剤の投与対象となる個体の選択方法
Lyman et al. Breast Cancer: Translational Therapeutic Strategies

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20100208

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110805

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120130

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120229

R150 Certificate of patent or registration of utility model

Ref document number: 4943504

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150309

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees